Co-delivery of DNAzyme and a chemotherapy drug using a DNA tetrahedron for enhanced anticancer therapy through synergistic effects. (20th August 2019)

• Record Type: Journal Article
• Authors: Ren, Tao; Deng, Zhiwei; Liu, Hui; Li, Xiufang; Li, Jianbing; Yuan, Jing; He, Yao; Liu, Qi; Yang, Yanjing; Zhong, Shian
• Is Part Of: New journal of chemistry. Volume 43:Number 35(2019)
• Page Start: 14020
• Page End: 14027
• Publication Date: 2019-08-20
• Subjects: Chemistry -- Periodicals; Chimie -- Périodiques; 540
• DOI: 10.1039/c9nj02818h
• Languages: English
• ISSNs: 1144-0546

Abstract

Abstract : Engineering of a DNA tetrahedron allows co-delivery of DOX and DNAzyme for chemo-gene synergistic therapy aiming at specific cells and their microenvironment. Abstract : A DNA tetrahedron, which could be rapidly and reliably assembled by annealing four customized ssDNA oligonucleotides, has been regarded as one of the most promising nanocarriers. However, engineering of a DNA tetrahedron allowing co-delivery of two or more drugs for synergistic therapy has been largely unexplored. Herein, we report a nanocarrier composed of a DNA tetrahedron (Td), a ZY11-targeting aptamer, anticancer drug doxorubicin (Dox), and 17E DNAzyme to achieve synergistic chemo-gene cancer therapy. First, the nanocarrier was assembled by annealing. Dox can be loaded onto the DNA tetrahedron through intercalation and released in a pH-dependent manner. The obtained Dox@Aptamer–Td–DNAzyme (Dox@Ap–Td–Dz) not only demonstrated an excellent efficiency of gene suppression but also exhibited a good pH-responsive drug release behavior. Hence, the presented DNA tetrahedron based multifunctional nanoplatform can achieve a targeted and synergistic chemo-gene therapy, which provides great potential in improving the curative efficiency.